No Detail Found!

Clinical efects of IPCH after the surgery for ovarian cancer at the middle or advanced stage and its impacts on tumor markers and immune functions

Author(s)
Heyue Li Division of Urological and Reproductive Medicine, Shanghai 7th People’s Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China
Yan Zhang Division of Urological and Reproductive Medicine, Shanghai 7th People’s Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China
Hong Tang Division of Urological and Reproductive Medicine, Shanghai 7th People’s Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China
Linxia Li Division of Urological and Reproductive Medicine, Shanghai 7th People’s Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China
Abstract
Objective: To evaluate the clinical efects of intraperitoneal chemohyperthermia (IPCH) in the treatment of postoperative patients with advanced stage ovarian cancer, and its impacts on tumor markers and immune functions. Methods: This is a retrospective study. One hundred and twenty patients with advanced stage ovarian cancer received in Shanghai 7th People's Hospital Afiliated to Shanghai University of Traditional Chinese Medicine from May 10, 2022 to June 10, 2023 were selected and randomly divided into control and study groups (n=60 each group). Patients in the control group were administered routine intravenous chemotherapy, the study group underwent IPCH besides routine intravenous chemotherapy based on the control group. Comparatively analyzed the clinical efects, adverse reaction occurrence rates, and variations in relevant observation targets, the tumor marker after and before the treatment. Results: Total eficacy in the study and control groups are proved to be with statistically significant diferences. The occurrence of adverse reactions proved that no significant diferences is seen between both groups. After the treatment, CEA, CA19-9, and CA125 levels in patients of the study group are apparently lower than those in the control group, showing statistically significant diferences; expression levels of CD3+, CD4+ and CD4+/CD8+, in the study group were enormously above those in the control group after the treatment, with statistically significant diferences. Conclusions: IPCH has the potential to efectively enhance comprehensively clinical therapeutic efects among postoperative patients with ovarian cancer, significantly improve patients' immune states, and evidently reduce expression levels of various tumor markers.
Publication Details
Page(s) 1919-1924
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 9, Year: 2024

Request the full text from PASTIC

Keywords
Immune function, Clinical Efect, Intraperitoneal chemohyperthermia, Advanced stage ovarian cancer
References
Morand S,Devanaboyina M,Staats H,Stanbery L,Nemunaitis J. Ovarian Cancer Personalized,Medicine Personalized .2021 .. Int J Mol Sci, 10(12) : 6532.
Stewart C,Ralyea C,Lockwood S. Ovarian C .2019 .Cancer: An Integrated Review. Semin Oncol Nurs, 02(2) : 151-156.
Lheureux S,Braunstein M,Oza AM .2019 .Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin, 10(4) : 280-304.
Eisenhauer EA .2017 .Real-world evidence in the treatment of ovarian cancer. Ann Oncol, 10(suppl) : viii61-viii65.
Su X,Sun X,Kang Y,Dai Y. .2022 .Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer. Pak J Med Sci, 10(4PartII) : 4736-877.
Lisio MA,Fu L,Goyeneche A,Gao ZH,Telleria C .2019 .High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci, 10(4) : 952.
Su X,Sun X,Wang Y,Kang Y,Dai Y. .2022 .Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer. Pak J Med Sci, 10(6) : 5287-1513.
Lalchandani UR,Sahai V,Hersberger K,Francis IR,Wasnik AP .2018 .A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors. Curr Probl Diagn Radiol, 07(6) : 576-585.
Vergote I,Harter P,Chiva L .2019 .Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer, 10(Suppl24) : 4594-4597.
van Stein RM,Aalbers AGJ,Sonke GS .2021 .Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review. JAMA Oncol, 10(8) : 1231-1238.
Kim SI,Kim JH,Lee S,Cho H,van Driel WJ,Sonke GS .2022 .Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis. Gynecol Oncol, 10(3) : 547-556.
Gajarawala S,Pelkowski J,Dorian R,Stanton A,Dinh T. .2021 .Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer. JAAPA, 0000735800(8) : 50-53.
Riggs MJ,Pandalai PK,Kim J,Dietrich CS .2020 .Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Diagnostics (Basel), 10(1) : 43.
Tsuyoshi H,Inoue D,Kurokawa T,Yoshida Y. .2020 .Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer. J Obstet Gynaecol Res, 10(9) : 1661-1671.
Kim SI,Kim JW .2021 .Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open, 10(3) : 100149.
van Driel WJ,Koole SN,Sikorska K,Schagen van Leeuwen JH,Schreuder HWR,Hermans RHM .2018 .. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med, 10(3) : 230-240.
Dong X,Men X,Zhang W .2014 .Advances in tumor markers of ovarian cancer for early diagnosis. Indian J Cancer, 10(Suppl3) : 154049-509X.
Lim MC,Chang SJ,Park B,Yoo HJ,Yoo CW,Nam BH .2022 .Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg, 10(5) : 374-383.
Anadon CM,Yu X,Hänggi K,Biswas S,Chaurio RA,Martin A .2022 .Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell, 03(5) : 545-557.
Hornburg M,Desbois M,Lu S,Guan Y,Lo AA,Kaufman S .2021 .Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell, 04(7) : 928-944.
Revaux A,Carbonnel M,Kanso F,Naoura I,Asmar J,Kadhel P .2020 .Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update. -0028, 10(3) : 10.
0

Citations

0

Downloads

85

Views